https://de.marketscreener.com/kurs/aktie/TAKEDA-PHARMACEUTICAL-COM-6491073/news/Takeda-Phase-3-Studie-zu-ALUNBRIG-Brigatinib-hat-primaren-Endpunkt-erreicht-Uberlegenheit-27006090/?utm_source=telegram&utm_medium=social&utm_campaign=share